BioCryst Pharmaceuticals (BCRX) : The highest level BioCryst Pharmaceuticals (BCRX) is projected to reach is $10 for the short term and the lowest estimate is at $3. The consolidated price target from 6 rating analysts who initiate coverage on the stock is $6.33 and the possibility the share price can swing is $2.88.
BioCryst Pharmaceuticals (BCRX) has an average broker rating of 2.13, which is interpreted as a Buy, as rated by 8 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 3 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 considers that the stock is a Sell.
Also, Equity Analysts at the PiperJaffray upgrades the rating on BioCryst Pharmaceuticals (NASDAQ:BCRX). The brokerage firm has issued a Overweight rating on the shares. The shares were previously rated Neutral. The rating by the firm was issued on August 12, 2016.
BioCryst Pharmaceuticals (NASDAQ:BCRX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.12 and $4.07 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.25. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.16, notching a gain of 1.22% for the day. The total traded volume was 393,134 . The stock had closed at $4.11 on the previous day.
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB, BCX4161, BCX7353 and other second generation HAE compounds, BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza, in the United States as RAPIVAB, in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Companys Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.